A5054462290- Immune cells in cancer
- Immune Cell Function and Interaction
- Histone Deacetylase Inhibitors Research
- Chemokine receptors and signaling
- Immunotherapy and Immune Responses
- Extracellular vesicles in disease
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Heat shock proteins research
- Inflammation biomarkers and pathways
- SARS-CoV-2 and COVID-19 Research
- Phagocytosis and Immune Regulation
- Cancer Cells and Metastasis
- Inflammatory Biomarkers in Disease Prognosis
- COVID-19 Clinical Research Studies
German Cancer Research Center
2020-2024
Heidelberg University
2020-2024
University Medical Centre Mannheim
2020-2024
University Hospital Heidelberg
2020-2024
University of Mannheim
2023
Background Myeloid-derived suppressor cells (MDSCs) represent a negative prognostic factor in malignant melanoma. These are generated under chronic inflammatory conditions typical of cancer. The transcription signal transducer and activator 3 (STAT3) orchestrates MDSC accumulation acquisition immunosuppressive properties. Here we studied STAT3 inhibition by Napabucasin as way to block activity its potential treat Methods In vitro murine primary from melanoma-bearing mice were used...
A gradual decay in humoral and cellular immune responses over time upon SAR1S-CoV-2 vaccination may cause a lack of protective immunity. We conducted longitudinal analysis antibodies, T cells, monocytes 25 participants vaccinated with mRNA or ChAdOx1-S up to 12 weeks after the 3 rd (booster) dose vaccine. observed substantial increase antibodies CD8 cells specific for spike protein SARS-CoV-2 vaccination. Moreover, induced activated expressing CD69, CD137 producing IFN-γ TNF-α....
Tumor cells modulate host immunity by secreting extracellular vesicles (EV) and soluble factors. Their interactions with myeloid lead to the generation of myeloid-derived suppressor (MDSC), which inhibit antitumor function T NK cells. We demonstrated previously that EV derived from mouse human melanoma induced immunosuppressive activity via increased expression programmed cell death ligand 1 (PD-L1) on was dependent heat-shock protein 90α (HSP90α) in EV. Here, we investigated whether HSP90α...
Background: Despite recent improvement in the treatment of malignant melanoma by immune-checkpoint inhibitors, disease can progress due to an immunosuppressive tumor microenvironment (TME) mainly represented myeloid-derived suppressor cells (MDSC). However, relative contribution polymorphonuclear (PMN) and monocytic (M) MDSC subsets progression is not clear. Here, we compared both regarding their capacity recruitment mechanisms. Furthermore, inhibited PMN-MDSC migration vivo determine its...
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation system followed by diverse immunological side effects known as immune-related adverse events (irAE). Currently, toxicity irAE is limiting usage ICIs. Here, we studied circulating monocytic myeloid-derived suppressor cells (M-MDSCs) and T in course after ICI therapy. Our longitudinal study involved 31 patients without during anti-PD-1 monotherapy or...
The ability of tumor-derived extracellular vesicles (EVs) to modulate the function myeloid cells is widely recognized. Hence, a comprehensive understanding distinct components associated with EVs and signals that they deliver could provide potential approaches impede immunosuppression by myeloid-derived suppressor (MDSCs). We investigated melanoma EV-associated microRNAs (miRs) using RET transgenic mouse model simulated their transfer normal transfecting immature human monocytes. observed...